advertisement
Journal of Ocular Pharmacology and Therapeutics 21
Showing records 1 to 21 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics90011 Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy
Rahman N
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 582-594
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Lin Z
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Tsukahara S
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Alagöz N
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Huang S
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Enomoto N
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Tellioglu A
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
90011 Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy
O'Neill E
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 582-594
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Bektasoglu DL
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Yu H
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Ishida K
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90011 Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy
Irnaten M; Wallace D
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 582-594
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Anraku A
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Sun J
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Yasar T
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
90701 One-Year Efficacy and Safety Assessment of Ripasudil, a Rho Kinase Inhibitor, in an Addition to or Replacing Existing Treatment Regimens: A Retrospective Study
Tomita G
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 512-521
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Huang P
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90011 Corneal Stiffness and Collagen Cross-Linking Proteins in Glaucoma: Potential for Novel Therapeutic Strategy
O'Brien C
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 582-594
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Basgil Pasaoglu I; Altan AC
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
90371 Analysis of Plasma Hydrogen Sulfide, Homocysteine, and L-Cysteine in Open-Angle Glaucoma Patients
Zhong Y
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 649-657
90160 Do We Conform with European Glaucoma Society Guidelines in the Medical Treatment of Primary Open-Angle Glaucoma/Ocular Hypertension? Data from a Real-Life Practice
Solmaz B; Basarır B
Journal of Ocular Pharmacology and Therapeutics 2020; 36: 747-753
